EnteroMedics Company Profile (NASDAQ:ETRM)

About EnteroMedics (ETRM)

EnteroMedics logoEnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: ETRM
  • CUSIP: 29365M20
Key Metrics:
  • Previous Close: $5.84
  • 50 Day Moving Average: $6.70
  • 200 Day Moving Average: $3.16
  • 52-Week Range: $1.75 - $86.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.05
  • P/E Growth: 0.00
  • Market Cap: $40.14M
  • Outstanding Shares: 6,873,000
  • Beta: 2.21
Profitability:
  • Net Margins: -3,236.52%
  • Return on Equity: -1,361.34%
  • Return on Assets: -190.05%
Debt:
  • Debt-to-Equity Ratio: 1.07%
  • Current Ratio: 1.20%
  • Quick Ratio: 0.93%

Analyst Ratings

Consensus Ratings for EnteroMedics (NASDAQ:ETRM) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.03 (20.38% upside)

Analysts' Ratings History for EnteroMedics (NASDAQ:ETRM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/9/2017S&P Equity ResearchLower Price Target$17.19 -> $11.06N/AView Rating Details
6/9/2016Roth CapitalDowngradeBuy -> Neutral$3.00 -> $3.00N/AView Rating Details
11/10/2015Canaccord GenuityLower Price Target$37.50 -> $15.00N/AView Rating Details
7/20/2015Craig HallumLower Price TargetBuy$75.00 -> $30.00N/AView Rating Details
(Data available from 3/23/2015 forward)

Earnings

Earnings History for EnteroMedics (NASDAQ:ETRM)
Earnings by Quarter for EnteroMedics (NASDAQ:ETRM)
Earnings History by Quarter for EnteroMedics (NASDAQ:ETRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017        
8/4/2016Q216($0.75)($0.49)ViewN/AView Earnings Details
5/5/2016Q1($0.80)($0.94)ViewN/AView Earnings Details
2/17/2016Q315($0.90)($0.95)ViewListenView Earnings Details
8/6/2015Q215($0.10)($0.10)ViewN/AView Earnings Details
2/18/2015Q414($0.10)($0.09)ViewN/AView Earnings Details
11/12/2014Q3 14($0.10)($0.08)ViewN/AView Earnings Details
8/7/2014Q2($0.10)($0.11)ViewListenView Earnings Details
4/30/2014Q1 14($0.10)($0.10)ViewN/AView Earnings Details
2/12/2014Q413($0.10)($0.11)ViewN/AView Earnings Details
10/31/2013Q313($0.11)($0.11)ViewN/AView Earnings Details
7/31/2013Q2 2013($0.13)($0.11)ViewN/AView Earnings Details
5/1/2013Q1 2013($0.13)($0.14)$0.10 millionViewN/AView Earnings Details
2/13/2013Q4 2012($0.14)($0.17)$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for EnteroMedics (NASDAQ:ETRM)
Current Year EPS Consensus Estimate: $-170.10 EPS
Next Year EPS Consensus Estimate: $-126.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.80)($0.05)($0.43)
Q2 20161($0.69)($0.69)($0.69)
Q3 20161($0.53)($0.53)($0.53)
Q4 20161($0.41)($0.41)($0.41)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for EnteroMedics (NASDAQ:ETRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for EnteroMedics (NASDAQ:ETRM)
Insider Ownership Percentage: 1.40%
Insider Trades by Quarter for EnteroMedics (NASDAQ:ETRM)
Institutional Ownership by Quarter for EnteroMedics (NASDAQ:ETRM)
Insider Trades by Quarter for EnteroMedics (NASDAQ:ETRM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/3/2016Peter M DelangeSVPBuy20,000$0.55$11,000.00View SEC Filing  
8/13/2015Mark B KnudsonCEOBuy303,000$0.25$75,750.00View SEC Filing  
6/19/2014Cathy FriedmanDirectorBuy11,800$1.70$20,060.00View SEC Filing  
1/8/2014Luke EvninDirectorSell556,585$2.50$1,391,462.50View SEC Filing  
2/27/2013Anthony P JanszDirectorBuy150,000$0.95$142,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for EnteroMedics (NASDAQ:ETRM)
Latest Headlines for EnteroMedics (NASDAQ:ETRM)
Source:
DateHeadline
streetinsider.com logoEnteroMedics (ETRM) Says vBloc Neurometabolic Therapy to be ... - StreetInsider.com (NASDAQ:ETRM)
www.streetinsider.com - March 15 at 2:30 AM
seekingalpha.com logoEnteroMedics: A High Risk Short Opportunity - Seeking Alpha (NASDAQ:ETRM)
seekingalpha.com - March 15 at 2:30 AM
finance.yahoo.com logoHere's Why EnteroMedics (ETRM) Stock Soared Today (NASDAQ:ETRM)
finance.yahoo.com - March 14 at 4:24 PM
finance.yahoo.com logoENTEROMEDICS INC Financials (NASDAQ:ETRM)
finance.yahoo.com - March 14 at 4:24 PM
finance.yahoo.com logoEnteroMedics' vBloc® Neurometabolic Therapy Featured on "The Doctors" TV Show (NASDAQ:ETRM)
finance.yahoo.com - March 13 at 5:07 PM
biz.yahoo.com logoENTEROMEDICS INC Files SEC form 10-K, Annual Report (NASDAQ:ETRM)
biz.yahoo.com - March 8 at 5:52 PM
baystreet.ca logoEnteroMedics (ETRM) Spikes Despite Q4 Loss (NASDAQ:ETRM)
www.baystreet.ca - March 7 at 11:43 AM
us.rd.yahoo.com logoEnteroMedics Reports Fourth Quarter 2016 Financial Results (NASDAQ:ETRM)
us.rd.yahoo.com - March 7 at 11:43 AM
biz.yahoo.com logoENTEROMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ETRM)
biz.yahoo.com - March 7 at 11:43 AM
streetinsider.com logoEnteroMedics (ETRM) Regains Compliance With Nasdaq Listing Requirement (NASDAQ:ETRM)
www.streetinsider.com - February 22 at 8:47 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating EnteroMedics Inc. for Potential Breaches … (NASDAQ:ETRM)
finance.yahoo.com - February 22 at 8:47 AM
us.rd.yahoo.com logoEnteroMedics Regains Compliance With Nasdaq Listing Requirement (NASDAQ:ETRM)
us.rd.yahoo.com - February 22 at 8:47 AM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating EnteroMedics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (NASDAQ:ETRM)
us.rd.yahoo.com - February 22 at 8:47 AM
biz.yahoo.com logoENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:ETRM)
biz.yahoo.com - February 14 at 11:04 PM
streetinsider.com logoEnteroMedics (ETRM) Announces 3-Year Data from vBloc Diabetic Patient Study Published in Journal of Diabetes and Obesity (NASDAQ:ETRM)
www.streetinsider.com - February 10 at 3:42 AM
streetinsider.com logoEnteroMedics (ETRM) Announces 3-Year Data from vBloc Diabetic ... - StreetInsider.com (NASDAQ:ETRM)
www.streetinsider.com - February 9 at 5:40 PM
us.rd.yahoo.com logoEnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity (NASDAQ:ETRM)
us.rd.yahoo.com - February 9 at 5:40 PM
us.rd.yahoo.com logo7:02 am EnteroMedics announces the publication of three-year data from the Company's VBLOC DM2 Study of vBloc Neurometabolic Therapy in obese patients with Type 2 diabetes (NASDAQ:ETRM)
us.rd.yahoo.com - February 9 at 5:40 PM
biz.yahoo.com logoENTEROMEDICS INC Files SEC form 8-K, Other Events (NASDAQ:ETRM)
biz.yahoo.com - February 8 at 5:35 PM
biz.yahoo.com logoENTEROMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ETRM)
biz.yahoo.com - January 24 at 5:44 PM
finance.yahoo.com logoEnteroMedics Announces Closing of $19.0 Million Underwritten Public Offering and Full Exercise of Over-allotment Option (NASDAQ:ETRM)
finance.yahoo.com - January 23 at 5:26 PM
benzinga.com logoEnteroMedics Short Squeeze Is Back In Play (NASDAQ:ETRM)
www.benzinga.com - January 21 at 4:23 AM
rttnews.com logoEnteromedics Inc. (ETRM) Is Accelerating Higher In Early Trade (NASDAQ:ETRM)
www.rttnews.com - January 21 at 4:23 AM
seekingalpha.com logoEnteroMedics tries to regain momentum; shares up 51% (NASDAQ:ETRM)
seekingalpha.com - January 20 at 11:05 AM

Social

Frequently Asked Questions for EnteroMedics (NASDAQ:ETRM)

What is EnteroMedics' stock symbol?

EnteroMedics trades on the NASDAQ under the ticker symbol "ETRM."

When did EnteroMedics' stock split? How did EnteroMedics' stock split work?

EnteroMedics shares reverse split on the morning of Friday, January 8th 2016. The 1-15 reverse split was announced on Wednesday, December 23rd 2015. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 7th 2016. An investor that had 100 shares of EnteroMedics stock prior to the reverse split would have 7 shares after the split.

How were EnteroMedics' earnings last quarter?

EnteroMedics Inc (NASDAQ:ETRM) announced its earnings results on Thursday, August, 4th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.26. EnteroMedics had a negative net margin of 3,236.52% and a negative return on equity of 1,361.34%.

When will EnteroMedics make its next earnings announcement?

EnteroMedics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

Where is EnteroMedics' stock going? Where will EnteroMedics' stock price be in 2017?

1 brokerages have issued 1 year target prices for EnteroMedics' stock. Their forecasts range from $3.00 to $11.06. On average, they expect EnteroMedics' share price to reach $7.03 in the next year.

Are investors shorting EnteroMedics?

EnteroMedics saw a increase in short interest in February. As of February 15th, there was short interest totalling 1,229,647 shares, an increase of 71.2% from the January 31st total of 718,396 shares. Based on an average daily volume of 3,008,913 shares, the days-to-cover ratio is currently 0.4 days. Currently, 29.0% of the company's stock are sold short.

Who owns EnteroMedics stock?

EnteroMedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (10.07%) and CVI Investments, Inc (0.30%). Company insiders that own EnteroMedics stock include Mark B Knudson and Peter M Delange.

Who sold EnteroMedics stock? Who is selling EnteroMedics stock?

EnteroMedics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy EnteroMedics stock?

Shares of EnteroMedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of EnteroMedics stock cost?

One share of EnteroMedics stock can currently be purchased for approximately $5.84.

EnteroMedics (ETRM) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by MarketBeat.com Staff